Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study

Ming Sheng Lim; Tishya Indran; Anita Cummins; Ashwini Bennett; Erica Wood; Susan Brown; Zoe McQuilten; Huyen Tran; Master Clin Epi; Noel C. Chan; Sanjeev Chunilal

doi:10.1055/s-0038-1676320

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2019; 45(02): 187-195
DOI: 10.1055/s-0038-1676320

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study

Ming Sheng Lim

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

,

Tishya Indran

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

,

Anita Cummins

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

,

Ashwini Bennett

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

,

Erica Wood

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

³Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

,

Susan Brown

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

,

Zoe McQuilten

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

³Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

,

Huyen Tran

,

Master Clin Epi

⁴The Australian Centre for Blood Diseases, Monash University, Alfred Medical Research and Educational Precinct, Melbourne, Australia

⁵Department of Clinical Hematology, The Alfred Hospital, Melbourne, Australia

,

Noel C. Chan

⁶Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada

⁷Department of Medicine, McMaster University, Hamilton, Ontario, Canada

,

Sanjeev Chunilal

¹Department of Hematology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia

²Faculty of Medicine Nursing and Health Science, Monash University, Melbourne, Victoria, Australia

› Author Affiliations

Abstract

The highest risk of adverse events for patients with acute venous thromboembolism (VTE) is during the early anticoagulation period. However, no established model exists for early clinical monitoring of patients treated with non–vitamin K antagonist oral anticoagulants (NOACs). The authors' aim was to evaluate the utility of a nurse-led pathway to minimize adverse events in acute VTE patients starting on rivaroxaban. The rivaroxaban VTE treatment pathway is a prospective cohort study of consecutive patients with objectively confirmed VTE between July 2015 and May 2017. Primary outcome was the proportion of patients identified at major risk of adverse events (bleeding or recurrent VTE). Secondary outcomes were rates of interventions, major or clinically relevant nonmajor bleeding (CRNMB), recurrent VTE, and all-cause mortality at 90 days. Among 304 participants, 5% (n = 15) were identified to be at major and 9% (n = 28) at possible risk for adverse events. Appropriate interventions to prevent harm were required in 40 patients. Rates of major bleeding, CRNMB, recurrence, and all-cause mortality were 0.3% (95% confidence interval [CI]: 0.1–1.8), 7.2% (95% CI: 4.8–10.7), 1.0 (95% CI: 0.3–2.9), and 1.6% (95% CI: 0.7–3.8), respectively. In conclusion, following discharge of acute VTE patients, a nurse-led pathway identified one in seven (14%) patients at major or possible risk of adverse events. Preemptive interventions to reduce harm translated into the low rates of bleeding and recurrence. The authors' experience highlights the feasibility and importance of a structured clinical surveillance pathway for acute VTE patients initiating NOAC therapy.

Keywords

adverse drug event - clinical pathways - nurse-led pathway - rivaroxaban - venous thromboembolism

Full Text

References

References
1 Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44 (02) 62-69
2 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
3 Pratt NL, Ramsay EN, Caughey GE, Shakib S, Roughead EE. Uptake of novel oral anticoagulants in Australia. Med J Aust 2016; 204 (03) 104-5 .e1
4 Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA 2016; 316 (20) 2115-2125
5 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
6 Büller HR, Prins MH, Lensin AWA. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
7 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
8 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
9 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
10 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
11 Larock A-S, Mullier F, Sennesael A-L. , et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 2014; 48 (10) 1258-1268
12 Chowdhry U, Jacques A, Karovitch A, Giguère P, Nguyen M-L. Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients. Can J Hosp Pharm 2016; 69 (03) 194-201
13 Tellor KB, Patel S, Armbruster AL, Daly MW. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther 2015; 40 (04) 447-451
14 Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J 2016; 46 (07) 812-818
15 Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11 (01) 177-179
16 Heidbuchel H, Verhamme P, Alings M. , et al; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (05) 625-651
17 Heidbuchel H, Berti D, Campos M. , et al. Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thromb J 2015; 13: 22
18 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
19 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. ; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
20 Condliffe R. Pathways for outpatient management of venous thromboembolism in a UK centre. Thromb J 2016; 14 (01) 47
21 Beyer-Westendorf J, Förster K, Pannach S. , et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124 (06) 955-962
22 Kucher N, Aujesky D, Beer JH. , et al. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost 2016; 116 (03) 472-479
23 Sindet-Pedersen C, Langtved Pallisgaard J, Staerk L. , et al. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study. Thromb Haemost 2017; 117 (06) 1182-1191
24 Larsen TB, Skjøth F, Kjældgaard JN, Lip GYH, Nielsen PB, Søgaard M. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematol 2017; 4 (05) e237 –e244
25 Ageno W, Mantovani LG, Haas S. , et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12 –e21
26 Gaertner S, Cordeanu E-M, Nouri S. , et al. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6-month outcomes. Int J Cardiol 2017; 226: 103-109
27 Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost 2017; 117 (10) 1841-1847
28 Tran E, Duckett A, Fisher S, Bohm N. Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. J Thromb Thrombolysis 2017; 43 (04) 505-513
29 Trujillo-Santos J, Di Micco P, Dentali F. , et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
30 De Crem N, Peerlinck K, Vanassche T. , et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 2015; 136 (04) 749-753
31 Martinelli I, Lensing AWA, Middeldorp S. , et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127 (11) 1417-1425

Supplementary Material

Supplementary Material